Literature DB >> 24831689

Antiphospholipid syndrome in Sarawak: real world experience in a developing country.

C L Teh1, T S Leong.   

Abstract

We performed a cross-sectional study of all antiphospholipid syndrome (APS) patients during an 8-year period (2006-2013) to describe the clinical features, serology profiles, treatment regimes, and outcomes in our center. There were a total of 59 patients in our study with the female to male ratio of 9:1. They have a mean age of 41.6 ± 12.1 years and a mean duration of illness of 38.4 ± 68.5 months. The majority of patients presented with vascular thrombosis (69.5 %) with equal arterial and venous involvements. Twenty-six patients (44.1 %) presented with obstetric complications with recurrent abortions (32.2 %) as the main manifestation. Most patients were on daily warfarin doses of 2-6 mg (91.0 %) with target INR of 2-3. There was neither recurrent thrombosis nor bleeding complications documented. There were 80 % live births following treatment in our patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831689     DOI: 10.1007/s10067-014-2671-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').

Authors:  Jose Luis Rodriguez-Garcia; Maria Laura Bertolaccini; Maria Jose Cuadrado; Giovanni Sanna; Oier Ateka-Barrutia; Munther A Khamashta
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

Review 3.  Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies.

Authors:  Cloé Comarmond; Patrice Cacoub
Journal:  Autoimmun Rev       Date:  2012-12-30       Impact factor: 9.754

4.  14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome.

Authors:  Ricard Cervera; Ignasi Rodríguez-Pintó; Serena Colafrancesco; Fabrizio Conti; Guido Valesini; Cristina Rosário; Nancy Agmon-Levin; Yehuda Shoenfeld; Claudia Ferrão; Raquel Faria; Carlos Vasconcelos; Flavio Signorelli; Gerard Espinosa
Journal:  Autoimmun Rev       Date:  2014-03-20       Impact factor: 9.754

5.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

6.  Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome.

Authors:  Y Fujieda; T Atsumi; O Amengual; T Odani; K Otomo; M Kato; K Oku; Y Kon; T Horita; S Yasuda; T Koike
Journal:  Lupus       Date:  2012-08-30       Impact factor: 2.911

7.  Hughes syndrome: a common problem in Kuwait hospitals.

Authors:  A N Malaviya; R Marouf; K Al-Jarallah; A Al-Awadi; K Al-Saied; S Al-Gaurer; A Khamis; I Al-Salem; R Raghupathy; M Al-Mazidi; F Serebour; I Umamaheswaran; M Mourou; M Mokhtar; M Qurtom; A Raoof Al-Shayeb; T Tarasevicius; M A Hussain
Journal:  Br J Rheumatol       Date:  1996-11

8.  The prevalence of anticardiolipin antibody in patients with systemic lupus erythematosus and its association with clinical manifestations.

Authors:  Zahra Basiri; Mahmoud Gholyaf; Mansureh Faridnia; Ebrahim Nadi; Mandana Bairanvand
Journal:  Acta Med Iran       Date:  2013

9.  Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort.

Authors:  B E Tan; B Y H Thong; S Shivananda; W W Han; H H Chng
Journal:  Lupus       Date:  2009-07       Impact factor: 2.911

10.  A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies.

Authors:  Catharyn Stern; Lawrence Chamley; Helen Norris; Lyndon Hale; H W Gordon Baker
Journal:  Fertil Steril       Date:  2003-08       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.